Nuveen’s Voyager Therapeutics VYGR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$452K Buy
117,100
+23,939
+26% +$94.2K ﹤0.01% 2881
2025
Q4
$366K Hold
93,161
﹤0.01% 2987
2025
Q3
$435K Hold
93,161
﹤0.01% 2944
2025
Q2
$290K Sell
93,161
-15,628
-14% -$50.4K ﹤0.01% 3071
2025
Q1
$368K Hold
108,789
﹤0.01% 2989
2024
Q4
$617K Hold
108,789
﹤0.01% 2909
2024
Q3
$636K Hold
108,789
﹤0.01% 2933
2024
Q2
$861K Buy
108,789
+19,424
+22% +$163K ﹤0.01% 2789
2024
Q1
$832K Hold
89,365
﹤0.01% 2775
2023
Q4
$754K Buy
89,365
+940
+1% +$6.82K ﹤0.01% 2850
2023
Q3
$685K Hold
88,425
﹤0.01% 2731
2023
Q2
$1.01M Buy
+88,425
New +$915K ﹤0.01% 2657
2021
Q2
Sell
-89,401
Closed -$421K 3541
2021
Q1
$421K Sell
89,401
-3,681
-4% -$25.1K ﹤0.01% 3126
2020
Q4
$665K Sell
93,082
-181,223
-66% -$1.74M ﹤0.01% 2949
2020
Q3
$2.93M Sell
274,305
-133,134
-33% -$1.56M ﹤0.01% 2197
2020
Q2
$5.14M Sell
407,439
-7,310
-2% -$85K ﹤0.01% 1883
2020
Q1
$3.79M Sell
414,749
-224
-0.1% -$2.57K ﹤0.01% 1869
2019
Q4
$5.79M Sell
414,973
-107,086
-21% -$1.56M ﹤0.01% 1907
2019
Q3
$8.98M Buy
522,059
+264,574
+103% +$5.55M ﹤0.01% 1643
2019
Q2
$7.01M Buy
+257,485
New +$5.89M ﹤0.01% 1810

Other funds holding VYGR

Nuveen's VYGR Position: Q1 2026 in Review

Nuveen increased its Voyager Therapeutics (VYGR) stake by 26% in Q1 2026, buying an estimated $94.2K and bringing the position to 117,100 shares worth $452K. The position accounts for ﹤0.01% of the portfolio, ranked #2881.

Nuveen first reported a position in VYGR in Q2 2019 and has held it in 20 quarters since. The position peaked at $8.98M in Q3 2019. 135 funds tracked by Wall St. Rank hold VYGR as of Q1 2026.

  • Nuveen held 117,100 shares of Voyager Therapeutics worth $452K as of Q1 2026.
  • Nuveen bought 23,939 Voyager Therapeutics shares in Q1 2026, an estimated $94.2K.
  • Voyager Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #2881 holding.
  • Nuveen first reported a position in Voyager Therapeutics in Q2 2019 and has held it in 20 quarters since.
  • Nuveen's Voyager Therapeutics position peaked at $8.98M in Q3 2019.
  • 135 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.